Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma

Nursing and Health Professions

• Patient 100%
• Docetaxel 20%
• Gemcitabine 20%
• Dose 15%
• Soft Tissue Sarcoma 15%
• Osteosarcoma 15%
• Diseases 10%
• Toxicity 10%
• Overall Survival 5%
• Anemia 5%
• Combination Therapy 5%
• Febrile Neutropenia 5%
• Chemotherapy 5%
• Progression Free Survival 5%
• Cancer Control 5%
• Thrombocytopenia 5%
• Procedures 5%
• Neutropenia 5%
• Anthracycline 5%
• Ifosfamide 5%
• Sarcoma 5%

Medicine and Dentistry

• Inpatient 30%
• Gemcitabine 20%
• Docetaxel 20%
• Osteosarcoma 15%
• Soft Tissue Sarcoma 15%
• Toxicity 10%
• Diseases 10%
• Man 10%
• Combination Therapy 5%
• Overall Survival 5%
• Anemia 5%
• Sarcoma 5%
• Progression Free Survival 5%
• Anthracycline 5%
• Thrombocytopenia 5%
• Age 5%
• Neutropenia 5%
• Febrile Neutropenia 5%
• Ifosfamide 5%

Pharmacology, Toxicology and Pharmaceutical Science

• Gemcitabine 20%
• Docetaxel 20%
• Osteosarcoma 15%
• Soft Tissue Sarcoma 15%
• Diseases 10%
• Toxicity 10%
• Sarcoma 5%
• Overall Survival 5%
• Progression Free Survival 5%
• Anthracycline 5%
• Neutropenia 5%
• Thrombocytopenia 5%
• Anemia 5%
• Febrile Neutropenia 5%
• Ifosfamide 5%